Vicore Pharma Holding AB has received encouraging news regarding its Phase 2b ASPIRE trial of buloxibutid for idiopathic pulmonary fibrosis (IPF). On October 22, 2026, the company announced that the independent Data Monitoring Committee (iDMC) recommended the trial continue without modification after a pre-planned futility analysis. This recommendation is significant as it allows Vicore to advance its research without interruption, potentially leading to new treatment options for patients suffering from this debilitating disease.
The ASPIRE trial is designed to assess the efficacy and safety of buloxibutid, an oral small-molecule angiotensin II type 2 receptor agonist. The trial has fully enrolled 378 patients and is set to report topline results in mid-2027. This timeline positions Vicore to deliver critical data that could impact the treatment landscape for IPF.
Background
Vicore Pharma Holding AB, incorporated in Sweden, operates in the pharmaceutical preparations sector (SIC 2834). The company is publicly traded on the Nasdaq under the ticker VCRE. Its focus is on developing innovative therapies for respiratory and fibrotic diseases, with buloxibutid being its lead program.
What the Filing Says
According to the recent filing, "the independent Data Monitoring Committee for the Phase 2b ASPIRE trial of buloxibutid in idiopathic pulmonary fibrosis has recommended that the trial continue without modification following a pre-planned futility analysis." This indicates that the trial is proceeding as planned, with no safety concerns raised by the committee.
Impact
This development is likely to affect various stakeholders, including patients enrolled in the trial, healthcare providers, and investors in Vicore Pharma. The continuation of the trial without modifications suggests confidence in the study's design and the potential efficacy of buloxibutid, which could lead to improved treatment options for IPF patients.
What's Next
The filing does not specify what happens next. However, Vicore Pharma will continue with the ASPIRE trial as planned, aiming for a 52-week readout in mid-2027.